Latest News | Zydus Inks Licensing Pact with Takeda to Sell GERD Drug
Get latest articles and stories on Latest News at LatestLY. Zydus Lifesciences on Wednesday said it has inked a licensing pact with Takeda to market a drug for the treatment of gastroesophageal reflux disease (GERD).
New Delhi, Jul 17 (PTI) Zydus Lifesciences on Wednesday said it has inked a licensing pact with Takeda to market a drug for the treatment of gastroesophageal reflux disease (GERD).
The company has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India, the drug firm said in a statement.
The drug will be marketed under the brand name Vault in the country, it added.
Under the terms of this agreement, Zydus will be marketing the drug in India.
"With a rich legacy in marketing gastrointestinal therapies in India, we have been offering different breakthrough clinical options across the spectrum," Zydus Lifesciences MD Sharvil Patel said.
Vonoprazan is approved by the DCGI (Drugs Controller General of India) for the treatment of adults with reflux esophagitis and other Acid Peptic Disorders (APD).
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)